Novartis pays $125M for Sironax brain delivery platform
Novartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an option it secured from the U.S.-Chinese biotech in July 2025. Sironax will retain rights to use the technology for selected assets.
Why it matters: The deal is part of a broader Novartis push to solve one of neurology’s biggest technical problems: getting large therapeutic molecules across the blood-brain barrier. Rather than betting on a single approach, the Swiss pharma is assembling several brain-shuttle technologies that could work with different drug classes.
How it works: Sironax’s platform consists of so-called brain delivery modules designed to transport large molecules into the brain. The company says they could be applied to monoclonal antibodies, peptides, proteins, gene therapies and other biologics across diseases including Alzheimer’s, Parkinson’s, Huntington’s and amyotrophic lateral sclerosis (ALS).
Zoom out: Sironax is not Novartis’ only bet in the field.
- In August 2025, Novartis paid BioArctic $30 million upfront for an option to combine the Swedish biotech’s BrainTransporter technology with an undisclosed Novartis antibody in neurodegeneration. The agreement carries up to $772 million in additional payments if Novartis exercises the option and development progresses.
- In January, Novartis struck a much larger deal with SciNeuro Pharmaceuticals for an Alzheimer’s antibody program incorporating its own blood-brain barrier shuttle technology. SciNeuro received $165 million upfront and could earn up to $1.5 billion in milestones.
Novartis itself highlighted Sironax and BioArctic as recent “brain shuttle technology” deals when presenting its $12 billion acquisition of Avidity Biosciences, suggesting delivery technology is becoming a deliberate part of its neuroscience strategy rather than a collection of isolated transactions.
Big picture: The blood-brain barrier protects the brain from potentially harmful substances, but it also keeps many drugs — particularly antibodies and other large biologics — from reaching therapeutic concentrations in the central nervous system.
- That has turned delivery into an increasingly competitive field. Improving brain exposure could not only make existing therapeutic approaches more effective but potentially make drug classes viable in neurological diseases where they were previously difficult to use.
Between the lines: The $125 million will help finance Sironax’s own pipeline. The company has three programs in Phase 1b/2: SIR2501, an allosteric SARM1 inhibitor being developed to prevent neuroaxonal damage; SIR4156, a NAMPT activator for metabolic dysfunction; and SIR9900, a brain-penetrant RIPK1 inhibitor for inflammatory and immunological diseases. SIR2501 has FDA Fast Track designation in chemotherapy-induced peripheral neuropathy.
What to watch: Novartis now has access to multiple technologies aimed at the same fundamental bottleneck. The next question is whether those platforms can translate improved brain penetration into a clinically meaningful advantage and which approach proves best suited to which therapeutic modality.
